FR2581060B1
(fr)
*
|
1985-04-25 |
1988-07-01 |
Pf Medicament |
Procede industriel d'obtention du midalcipran
|
FR2581059B1
(fr)
*
|
1985-04-25 |
1988-04-22 |
Pf Medicament |
Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
|
EP0747348A4
(de)
*
|
1994-02-22 |
1999-07-07 |
Asahi Chemical Ind |
Aminoalkylcyclopropan-derivate
|
CA2134038C
(en)
*
|
1994-06-16 |
1997-06-03 |
David Taiwai Wong |
Potentiation of drug response
|
EP0714663A3
(de)
|
1994-11-28 |
1997-01-15 |
Lilly Co Eli |
Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
|
EP0759299B1
(de)
*
|
1995-08-16 |
2000-04-26 |
Eli Lilly And Company |
Potenzierung von Serotonin-Wirkstoffresponz
|
FR2752732B1
(fr)
*
|
1996-08-28 |
1998-11-20 |
Pf Medicament |
Forme galenique a liberation prolongee de milnacipran
|
MXPA04003358A
(es)
*
|
2001-10-12 |
2004-07-08 |
Serenix Pharmaceuticals Llc |
Antagonistas de vasopresina v1a de ?-lactamilo.
|
US6602911B2
(en)
*
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
US6635675B2
(en)
|
2001-11-05 |
2003-10-21 |
Cypress Bioscience, Inc. |
Method of treating chronic fatigue syndrome
|
US20040034101A1
(en)
*
|
2001-11-05 |
2004-02-19 |
Cypress Bioscience, Inc. |
Treatment and prevention of depression secondary to pain (DSP)
|
AU2003225206B2
(en)
*
|
2002-04-24 |
2008-02-14 |
Forest Laboratories Holdings Limited |
Prevention and treatment of functional somatic disorders, including stress-related disorders
|
JP4288263B2
(ja)
*
|
2002-10-25 |
2009-07-01 |
コレジウム ファーマシューティカル, インク. |
p−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
|
FR2851163B1
(fr)
*
|
2003-02-14 |
2007-04-27 |
|
Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
|
MXPA05008652A
(es)
*
|
2003-02-14 |
2005-10-18 |
Pf Medicament |
Uso del enantiomero (1s,2r) de milnacipran para la preparacion de un medicamento.
|
CA2522666A1
(en)
*
|
2003-04-18 |
2004-10-28 |
Pharmacia & Upjohn Company Llc |
Combination therapies for chronic obstructive pulmonary disease (copd)
|
CN1867549B
(zh)
*
|
2003-08-15 |
2011-07-06 |
H·隆德贝克有限公司 |
作为nk3受体拮抗剂的环丙基衍生物
|
NZ544935A
(en)
*
|
2003-08-15 |
2009-08-28 |
Lundbeck & Co As H |
Cyclopropyl derivatives as NK3 receptor antagonists
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
CA2567249A1
(en)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
AU2006227199A1
(en)
|
2005-03-22 |
2006-09-28 |
Azevan Pharmaceuticals, Inc. |
Beta-lactamylalkanoic acids for treating premenstrual disorders
|
EP1871356A1
(de)
*
|
2005-04-22 |
2008-01-02 |
Wyeth a Corporation of the State of Delaware |
Dihydrobenzofuran-derivate und verwendungen dafür
|
PE20061298A1
(es)
*
|
2005-04-22 |
2006-12-24 |
Wyeth Corp |
Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
|
CA2605554A1
(en)
*
|
2005-04-22 |
2006-11-02 |
Wyeth |
Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
|
CA2611724C
(en)
*
|
2005-06-10 |
2014-07-29 |
Pierre Fabre Medicament S.A. |
Stabilized milnacipran formulation
|
NZ565683A
(en)
|
2005-07-08 |
2011-04-29 |
Braincells Inc |
Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
|
CN101268068B
(zh)
*
|
2005-07-19 |
2015-12-02 |
阿泽范药品公司 |
β-内酰胺基苯丙氨酸、半胱氨酸和丝氨酸血管加压素拮抗剂
|
WO2007025144A1
(en)
*
|
2005-08-24 |
2007-03-01 |
University Of Illinois - Chicago |
5-ht2c receptor agonists as anorectic agents
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
EP1940389A2
(de)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation von neurogenese durch pde-hemmung
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US20080319083A1
(en)
*
|
2006-01-27 |
2008-12-25 |
Asahi Kasei Pharma Corporation |
Medicine for transnasal administration
|
KR20080091261A
(ko)
*
|
2006-01-27 |
2008-10-09 |
아사히 가세이 파마 가부시키가이샤 |
경비 투여용 약제
|
FR2912057B1
(fr)
*
|
2007-02-07 |
2009-04-17 |
Sanofi Aventis Sa |
Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20070225279A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Therapeutic combinations for the treatment of depression
|
US7858611B2
(en)
*
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
MX2008014320A
(es)
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
TW200817003A
(en)
*
|
2006-07-31 |
2008-04-16 |
Sanofi Aventis |
Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
|
EP2068872A1
(de)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Kombinationen mit einem 4-acylaminopyridin-derivat
|
US20100016274A1
(en)
*
|
2006-09-14 |
2010-01-21 |
Koppel Gary A |
Beta-lactam cannabinoid receptor modulators
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008083204A2
(en)
*
|
2006-12-28 |
2008-07-10 |
Braincells, Inc. |
Modulation of neurogenesis by melatoninergic ligands
|
CA2675132A1
(en)
*
|
2007-01-11 |
2008-07-17 |
Braincells, Inc. |
Modulation of neurogenesis with use of modafinil
|
EP2114868A2
(de)
*
|
2007-02-28 |
2009-11-11 |
Ranbaxy Laboratories Limited |
Neuartige polymorphe formen von milnacipran-hydrochlorid
|
WO2009023820A1
(en)
*
|
2007-08-16 |
2009-02-19 |
Cypress Biosciences, Inc. |
Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
|
US20090069431A1
(en)
*
|
2007-09-12 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched milnacipran
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010036773A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
|
FR2941454B1
(fr)
|
2009-01-29 |
2011-04-01 |
Pf Medicament |
Proced de synthese du (1s,2r)-milnacipran
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20100274050A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Glenmark Generics Limited |
Solid milnacipran and process for the preparation of the same
|
US20100286260A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Forest Laboratories Holdings Ltd. |
Milnacipran formulations
|
CA2775091A1
(en)
|
2009-08-05 |
2011-02-10 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
US8865937B2
(en)
*
|
2009-11-06 |
2014-10-21 |
Mahendra G. Dedhiya |
Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
|
WO2011092065A1
(en)
|
2010-01-29 |
2011-08-04 |
Nicox S.A. |
Nitric oxide releasing compounds for the treatment of neurophatic pain
|
WO2012003436A1
(en)
|
2010-07-01 |
2012-01-05 |
Azevan Pharmaceuticals, Inc. |
Methods for treating post traumatic stress disorder
|
US8916194B2
(en)
|
2010-08-30 |
2014-12-23 |
Lupin Limited |
Controlled release pharmaceutical compositions of milnacipran
|
US20120289744A1
(en)
|
2010-11-03 |
2012-11-15 |
Arch Pharmalabs Limited |
Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
|
WO2012145234A2
(en)
*
|
2011-04-21 |
2012-10-26 |
Emory University |
Cyclopropyl derivatives and methods of use
|
WO2014009767A1
(en)
|
2012-07-07 |
2014-01-16 |
Micro Labs Limited |
An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
|
WO2014203277A2
(en)
*
|
2013-06-19 |
2014-12-24 |
Msn Laboratories Private Limited |
Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
|
WO2015044962A1
(en)
|
2013-09-30 |
2015-04-02 |
Cadila Healthcare Limited |
Amorphous form of levomilnacipran hydrochloride and hydrates thereof
|
SG11201608064WA
(en)
|
2014-03-28 |
2016-10-28 |
Azevan Pharmaceuticals Inc |
Compositions and methods for treating neurodegenerative diseases
|
US11628160B2
(en)
|
2017-09-15 |
2023-04-18 |
Azevan Pharmaceuticals, Inc. |
Compositions and methods for treating brain injury
|